Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis

Molecular and Cellular Biochemistry

Volumn 316, Issue 1-2, 2008, Pages 155-161

  Di Maira, Giovanni ^a,b   Brustolon, Francesca ^a,b   Tosoni, Kendra ^a,b   Belli, Sara ^c   Krämer, Stefanie D ^c   Pinna, Lorenzo A ^b   Ruzzene, Maria ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c ETH ZURICH   (Switzerland)

Author keywords

Apoptosis; Casein kinase; CK2; CKII; MDR; Resistance

Indexed keywords

CASEIN KINASE II; CASEIN KINASE IIALPHA; CASEIN KINASE IIBETA; CYTOTOXIC AGENT; GLYCOPROTEIN P; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; CASEIN KINASE II; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS;

EID: 50649116375     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9813-6     Document Type: Article

References (20)

1. Pinna LA (2002) Protein kinase CK2: A challenge to canons. J Cell Sci 115:3873-3878. doi: 10.1242/jcs.00074
2. Pinna LA (1990) Casein kinase 2: An "eminence grise" in cellular regulation? Biochim Biophys Acta 1054:267-284. doi: 10.1016/ 0167-4889(90)90098-X
3. Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349-368. doi: 10.1096/fj.02-0473rev
4. Ahmed K, Gerber DA, Cochet C (2002) Joining the cell survival squad: An emerging role for protein kinase CK2. Trends Cell Biol 12:226-230. doi: 10.1016/S0962-8924(02)02279-1
5. Litchfield DW (2003) Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem J 369:1-15. doi: 10.1042/BJ20021469
6. Borst P (1997) Multidrug resistant proteins. Semin Cancer Biol 8:131-134. doi: 10.1006/scbi.1997.0072
7. Sawicka M, Kalinowska M, Skierski J, Lewandowski W (2004) A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. J Pharm Pharmacol 56:1067-1081. doi: 10.1211/ 0022357044265
8. Szyszka R, Grankowski N, Felczak K, Shugar D (1995) Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources. Biochem Biophys Res Commun 208:418-424. doi: 10.1006/bbrc.1995.1354
9. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, Pinna LA (2004) 2-Dimethylamino-4, 5, 6, 7-tetrabromo-1H-benzimidazole: A novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321:1040-1044. doi: 10.1016/j.bbrc.2004.07.067
10. Cenni V, Maraldi NM, Ruggeri A, Secchiero P, Del Coco R, De Pol A et al (2004) Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. Int J Oncol 25:1599-1608
11. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42:872-881. doi: 10.1016/j.freeradbiomed.2006.12.021
12. Bucher K, Belli S, Wunderli-Allenspach H, Krämer SD (2007) P-glycoprotein in proteoliposomes with low residual detergent: The effects of cholesterol. Pharm Res 24:1993-2004. doi: 10.1007/ s11095-007-9326-0
13. Ruzzene M, Penzo D, Pinna LA (2002) Protein kinase CK2 inhibitor 4, 5, 6, 7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364:41-47
14. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA et al (2007) Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 26:6915-6926. doi: 10.1038/sj.onc.1210495
15. Ling V (1997) Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40(Suppl):S3-S8. doi: 10.1007/ s002800051053
16. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478:23-43. doi: 10.1016/S0027-5107(01)00141-5
17. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A et al (2001) Selectivity of 4, 5, 6, 7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ("casein kinase-2"). FEBS Lett 496:44-48. doi: 10.1016/S0014-5793(01)02404-8
18. Glavy JS, Horwitz SB, Orr GA (1997) Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein. J Biol Chem 272:5909-5914. doi: 10.1074/jbc.272.9.5909
19. Salvi M, Sarno S, Marin O, Meggio F, Itarte E, Pinna LA (2006) Discrimination between the activity of protein kinase CK2 holoenzyme and its catalytic subunits. FEBS Lett 580:3948-3952. doi: 10.1016/ j.febslet.2006.06.031
20. Filhol O, Martiel JL, Cochet C (2004) Protein kinase CK2: A new view of an old molecular complex. EMBO Rep 5:351-355. doi: 10.1038/ sj.embor.7400115